Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk

Core Insights - The Trump administration has reached agreements with Eli Lilly and Novo Nordisk to significantly reduce the prices of their weight loss drugs, making them more accessible to patients [1][4]. Pricing Structure - Monthly out-of-pocket costs for the weight loss injections and upcoming pills will range from $50 to $350, depending on dosage and insurance coverage [2]. - Current GLP-1 drugs, such as Zepbound and Wegovy, have list prices exceeding $1,000 per month, limiting patient access [3]. Medicare Coverage - Starting mid-2026, Medicare will cover GLP-1 drugs for obesity for the first time, potentially increasing access for seniors [5]. - Certain Medicare patients will pay a copay of $50 per month for approved uses of GLP-1 drugs, including obesity treatment [5]. Eligibility Criteria - Eligibility for GLP-1 drugs under Medicare is limited to three cohorts: individuals with a BMI greater than 27, those with obesity and specific health conditions, and patients with severe obesity (BMI greater than 35) [9]. Direct-to-Consumer Pricing - The TrumpRx platform will offer GLP-1s at lower prices, starting at $350 per month and expected to drop to $250 within two years [7]. - Eli Lilly plans to reduce prices on its direct-to-consumer platform, LillyDirect, with Zepbound available for $299 per month at the lowest dose [11]. Medicaid Coverage - Novo Nordisk and Eli Lilly will extend lower government pricing of $245 per month for GLP-1 drugs to all 50 Medicaid programs, although states must opt into these prices [12].